JP2009502121A - Ｌｅｆｔｙ、Ｌｅｆｔｙ誘導体およびそれらの使用 - Google Patents

Ｌｅｆｔｙ、Ｌｅｆｔｙ誘導体およびそれらの使用 Download PDF

Info

Publication number
JP2009502121A
JP2009502121A JP2008519739A JP2008519739A JP2009502121A JP 2009502121 A JP2009502121 A JP 2009502121A JP 2008519739 A JP2008519739 A JP 2008519739A JP 2008519739 A JP2008519739 A JP 2008519739A JP 2009502121 A JP2009502121 A JP 2009502121A
Authority
JP
Japan
Prior art keywords
lefty
polypeptide
recombinant
myostatin
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008519739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502121A5 (cg-RX-API-DMAC10.html
Inventor
ジョン クノッフ，
ジャスビー セーラ，
ラビンドラ クマール，
Original Assignee
アクセルロン ファーマ インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクセルロン ファーマ インコーポレーテッド filed Critical アクセルロン ファーマ インコーポレーテッド
Publication of JP2009502121A publication Critical patent/JP2009502121A/ja
Publication of JP2009502121A5 publication Critical patent/JP2009502121A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
JP2008519739A 2005-07-01 2006-06-30 Ｌｅｆｔｙ、Ｌｅｆｔｙ誘導体およびそれらの使用 Withdrawn JP2009502121A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69622605P 2005-07-01 2005-07-01
PCT/US2006/026443 WO2007006025A2 (en) 2005-07-01 2006-06-30 Lefty, lefty derivatives and uses therof

Publications (2)

Publication Number Publication Date
JP2009502121A true JP2009502121A (ja) 2009-01-29
JP2009502121A5 JP2009502121A5 (cg-RX-API-DMAC10.html) 2009-08-13

Family

ID=37605233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008519739A Withdrawn JP2009502121A (ja) 2005-07-01 2006-06-30 Ｌｅｆｔｙ、Ｌｅｆｔｙ誘導体およびそれらの使用

Country Status (6)

Country Link
US (2) US7612040B2 (cg-RX-API-DMAC10.html)
EP (1) EP1899369A2 (cg-RX-API-DMAC10.html)
JP (1) JP2009502121A (cg-RX-API-DMAC10.html)
AU (1) AU2006264339A1 (cg-RX-API-DMAC10.html)
CA (1) CA2613320A1 (cg-RX-API-DMAC10.html)
WO (1) WO2007006025A2 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022514939A (ja) * 2018-12-20 2022-02-16 チョングンダン ファーマシューティカル コーポレーション ヒトＬｅｆｔｙ Ａタンパク質変異体を含む融合タンパク質及びその用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5693004B2 (ja) * 2006-07-28 2015-04-01 チルドレンズ メモリアル ホスピタル ヒト胚性幹細胞の微小環境を使用して腫瘍細胞の悪性度を抑制する方法
US8106004B2 (en) * 2006-07-28 2012-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
JP6401172B2 (ja) * 2012-10-24 2018-10-10 セルジーン コーポレイション 貧血の治療方法
US10117908B2 (en) 2013-10-17 2018-11-06 Grant Labs, Inc. Suppression of cellular transformation and dysplasia by topical application of lefty
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916751A (en) 1996-08-27 1999-06-29 University Of South Florida Method for the diagnosis of selected adenocarcinomas
US6683156B1 (en) 1996-08-27 2004-01-27 University Of South Florida Method for diagnosing selected adenocarcinomas
US6294662B1 (en) 1996-08-27 2001-09-25 University Of South Florida Nucleic acids encoding an endometrial bleeding associated factor (ebaf)
US6635480B1 (en) 1997-07-31 2003-10-21 The Johns Hopkins University School Of Medicine Growth differentiation factor, lefty-2
WO1999006444A1 (en) 1997-07-31 1999-02-11 The Johns Hopkins University Of School Of Medicine GROWTH DIFFERENTIATION FACTOR, Lefty-1
US20020086351A1 (en) * 1998-08-20 2002-07-04 Reinhard Ebner Human nodal and lefty homologues
US6440694B1 (en) * 1997-09-30 2002-08-27 Pharmacia & Upjohn Company TNF-related death ligand
US6027917A (en) 1997-12-10 2000-02-22 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-17 and BMP-18 compositions
AU5087799A (en) * 1998-07-06 2000-01-24 Beth Israel Deaconess Medical Center Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis
WO2000066068A2 (en) 1999-04-29 2000-11-09 North Shore Long Island Jewish Research Corporation Method for inducing growth and enhancing survival of nervous tissue
WO2002012336A2 (en) * 2000-08-09 2002-02-14 Curis, Inc. TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE
US6649588B1 (en) 2000-10-05 2003-11-18 North Shore - Long Island Jewish Research Institute Inhibition of TGF-β and uses thereof
EP1539941A4 (en) * 2002-08-27 2006-11-29 ADZYMES AND THEIR USES
US7355018B2 (en) * 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022514939A (ja) * 2018-12-20 2022-02-16 チョングンダン ファーマシューティカル コーポレーション ヒトＬｅｆｔｙ Ａタンパク質変異体を含む融合タンパク質及びその用途
JP7355828B2 (ja) 2018-12-20 2023-10-03 チョングンダン ファーマシューティカル コーポレーション ヒトＬｅｆｔｙ Ａタンパク質変異体を含む融合タンパク質及びその用途

Also Published As

Publication number Publication date
EP1899369A2 (en) 2008-03-19
CA2613320A1 (en) 2007-01-11
WO2007006025A3 (en) 2007-05-31
US20100160225A1 (en) 2010-06-24
AU2006264339A1 (en) 2007-01-11
US7612040B2 (en) 2009-11-03
US20070042958A1 (en) 2007-02-22
WO2007006025A2 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
EP1771470B1 (en) Actrii receptor polypeptides, methods and compositions
JP2021097697A (ja) フォリスタチン関連融合タンパク質およびその使用
US8796199B2 (en) Uses of Cerberus and derivatives thereof
US20100160225A1 (en) Lefty, lefty derivatives and uses thereof
AU2017208295B2 (en) ActRII receptor polypeptides, methods and compositions
US9045553B2 (en) Cerberus/Coco derivatives and uses thereof
AU2012244215B2 (en) ActRII receptor polypeptides, methods and compositions
GB2372037A (en) G protein coupled receptor Fitz2
HK1156956B (en) Actrii receptor polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100622

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20101021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101109